Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 705564 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) and Food Effect on a Tablet Formulation of BI 705564 (Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Design) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs BI 705564 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 05 Sep 2017 Planned number of patients changed from 96 to 88.
- 05 Sep 2017 Planned End Date changed from 15 Nov 2017 to 18 Dec 2017.
- 05 Sep 2017 Planned primary completion date changed from 15 Nov 2017 to 18 Dec 2017.